Rilotumumab

Rilotumumab (AMG 102) is an anti-HGF (anti-hepatocyte growth factor) monoclonal antibody, inhibits HGF/MET-driven signaling. Rilotumumab shows anti-tumor activity, and can be used in castration-resistant prostate cancer (CRPC) and solid tumor research[1][2].

Product Specifications

CAS Number

[872514-65-3]

Product Name Alternative

AMG 102

UNSPSC

12352203

Target

C-Met/HGFR

Type

Inhibitory Antibodies

Related Pathways

Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/rilotumumab.html

Purity

99.10

Solubility

10 mM in DMSO

Smiles

[Rilotumumab]

Molecular Weight

(145.2 kDa)

References & Citations

[1]Ryan CJ, et al. Targeted MET inhibition in castration-resistant prostate cancer: a randomized phase II study and biomarker analysis with rilotumumab plus mitoxantrone and prednisone. Clin Cancer Res. 2013 Jan 1;19 (1) :215-24.|[2]Greenall SA, et al. EGFRvIII-mediated transactivation of receptor tyrosine kinases in glioma: mechanism and therapeutic implications. Oncogene. 2015 Oct 8;34 (41) :5277-87.